Compare EOD & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EOD | FHTX |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 271.7M | 323.4M |
| IPO Year | N/A | 2020 |
| Metric | EOD | FHTX |
|---|---|---|
| Price | $6.51 | $4.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $11.50 |
| AVG Volume (30 Days) | 87.1K | ★ 129.0K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 9.28% | N/A |
| EPS Growth | N/A | ★ 25.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,909,000.00 |
| Revenue This Year | N/A | $8.89 |
| Revenue Next Year | N/A | $20.13 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 36.75 |
| 52 Week Low | $5.14 | $3.27 |
| 52 Week High | $6.59 | $6.95 |
| Indicator | EOD | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 58.80 | 46.02 |
| Support Level | $5.58 | $3.65 |
| Resistance Level | $6.59 | $5.82 |
| Average True Range (ATR) | 0.10 | 0.27 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 60.93 | 58.87 |
Allspring Global Dividend Opportunity Fund is a diversified closed-end management investment company. Its primary investment objective is to seek a high level of current income. The fund's secondary objective is the long-term growth of capital. The fund allocates its assets between two separate investment strategies or sleeves. Under normal market conditions, the fund allocates approximately 80% of its total assets to an equity sleeve comprised of common stocks.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.